Jiangsu Recbio Technology Co Ltd

Jiangsu Recbio Technology Co Ltd operates with a capital structure that includes total liabilities of CNY 10.56 billion and total equity of CNY 7.06 billion, resulting in a debt-to-equity ratio of 0.9. The company holds CNY 351.84 million in cash and equivalents, but its long-term debt of CNY 638.47 million suggests a net cash position that is negative after subtracting total debt. The current ratio of 1.0 indicates that the company's current assets are equal to its current liabilities, suggesting limited liquidity buffer. Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of CNY 610.39 million and an operating loss of CNY 584.27 million, with a return on equity of -86.48% and a return on assets of -34.65%. These figures are well below the typical performance of companies in the Biotechnology & Medical Research industry, which often exhibit high R&D costs but also high potential for future returns. The company's revenue of CNY 12.73 million is minimal compared to its peers, and there is no disclosed geographic or segment breakdown in the provided data. Given that the company is still in the research and development stage, it is likely that all revenue is derived from its vaccine pipeline, though specific segment details are not available. Looking ahead, the company's growth trajectory is uncertain. The outlook for the current fiscal year does not include revenue growth, and the next fiscal year's direction is similarly unclear due to the absence of disclosed revenue history beyond the latest period. The company's risk assessment highlights medium liquidity risk and low dilution risk, but the key flag of negative net cash after debt suggests potential challenges in maintaining operations without additional financing. Recent events include the continued development of its vaccine pipeline, which includes a 9-valent HPV vaccine and other novel adjuvanted vaccines. No recent filings or transcripts are provided in the input data, so the narrative is based on the latest disclosed financial and operational status.